

1642.
JFW

PTO/SB/21 (04-04)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	10/044,692	
	Filing Date	January 11, 2002	
	First Named Inventor	Thomas R. Cech, et al.	
	Art Unit	1642	
	Examiner Name	Susan Nmn Ungar	
Total Number of Pages in This Submission	5	Attorney Docket Number	015389-0026400US; 018/213C


ENCLOSURES (Check all that apply)		
<input type="checkbox"/> Fee Transmittal Form (in duplicate)	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> After Allowance communication to Technology Center (TC)
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment/Reply	<input type="checkbox"/> Petition	<input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request (in duplicate)	<input type="checkbox"/> Terminal Disclaimer	<input checked="" type="checkbox"/> Other Enclosure(s) (please Identify below):
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Request for Refund	
<input checked="" type="checkbox"/> Supplemental Information Disclosure Statement (2 pages)	<input type="checkbox"/> CD, Number of CD(s) _____	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/Incomplete Application	Form PTO-1449 (2 pages) with copies of 25 references	
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name	J. Michael Schiff, Registration No. 40,253
Signature	
Date	June 28/04

CERTIFICATE OF TRANSMISSION/MAILING			
I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below.			
Typed or printed name	Karen Zielen		
Signature		Date	June 28, 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



CERTIFICATE OF FIRST CLASS MAIL

I hereby certify that this paper is being deposited with the United States Postal Service as First Class Mail addressed to the Commissioner for Patents & Trademarks, P.O. Box 1450, Arlington, VA 22313-1450, on the date indicated.

Karen Ziden
Name

June 28, 2004
Date

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of: Thomas R. Cech, *et al.*

Serial No.: 10/044,692

Filing Date: January 11, 2002

Attorney Docket: 018/213C

For: HUMAN TELOMERASE CATALYTIC
SUBUNIT: DIAGNOSTIC AND
THERAPEUTIC METHODS

Art Unit: 1642

Examiner: Susan Nmn Ungar

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
Arlington, VA 22313-1450


Dear Sir:

The information listed in the accompanying form PTO-1449 and provided herewith may be material to examination of this application and is submitted in compliance with the duty of disclosure under 37 CFR § 1.56. The Examiner is requested to make this information of record in the application.

This Information Disclosure Statement is not to be construed as a representation that a full search for relevant information has been made, that all relevant information has been found, or that the information provided with this Statement is considered to be material to patentability of the claimed invention as defined under 37 CFR § 1.56(b).

It is believed that no fee is required for submission of this Statement, which is filed before the first Office Action on the merits of the application. Nevertheless, should a fee be required for consideration of this Statement and the listed information, the Commissioner is authorized to charge such fee to Deposit Account No. 07-1139, referencing the attorney Docket Number indicated above.

Respectfully submitted,

A handwritten signature in black ink, appearing to read 'J. Michael Schiff', is written over a large, stylized circular mark.

J. Michael Schiff
Registration No. 40,253

GERON CORPORATION
230 Constitution Drive
Menlo Park, CA 94025
Telephone: (650) 473-7715
Fax: (650) 473-8654

June 25, 2004

Form 1449 (modified)	Docket: 018/213C	U.S.S.N.: 10/044,692
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Title: Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic Methods Inventors: Thomas R. Cech, <i>et al.</i>	
(Use Several Sheets if Necessary)	Filing Date: January 11, 2002	Group: 1642



U.S. PATENT DOCUMENTS

Examiner Initial	Ref.	Document No.	Filing Date	Publication Date	Class/ Subclass	Inventors	Title
	EA	5,853,719	Apr 30/96	Dec 29/98	424/93.21	Nair SK et al	Methods for Treating Cancers and Pathogen Infections Using Antigen-Presenting Cells Loaded with RNA
	EB	6,306,388	May 6/98	Oct 23/01	424/93.21	Nair SK et al	Methods for Treating Cancers and Pathogen Infections Using Antigen-Presenting Cells Loaded with RNA
	EC	6,387,701	Apr 30/99	May 14/02	435/455	Nair SK et al	Method of Identifying Tumor Antigens that Elicit a T-Cell Response
	ED	6,440,735	Sep 28/00	Aug 27/02	435/372.2	Gaeta FCA	Dendritic Cell Vaccine Containing Telomerase Reverse Transcriptase for the Treatment of Cancer

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner Initial	Ref.	Document No.	Publication Date	Jurisdiction	Title	Translation
	EE	EP 1093381 B1	Aug 20/03	EP	Antigenic Peptides Derived from Telomerase	N/A
	EF	WO 99/63945	Dec 16/99	PCT	Vaccination Strategy to Prevent and Treat Cancers	N/A
	EG	WO 00/61766	Oct 19/00	PCT	Telomerase-Specific Cancer Vaccine	N/A
	EH	WO 00/73420	Dec 7/00	PCT	Creation of Human Tumorigenic Cells and Uses Therefor	N/A
	EI	WO 01/60391	Aug 23/01	PCT	A Universal Vaccine and Method for Treating Cancer Employing Telomerase Reverse Transcriptase	N/A
	EJ	WO 02/094213	Nov 28/02	PCT	Polyorganosiloxane Micro-Emulsion Composition and Raw Material for Cosmetics	N/A
	EK	WO 03/038047	May 8/03	PCT	Human Telomerase Reverse Transcriptase as a Class-II Restricted Tumor-Associated Antigen	N/A


OTHER DOCUMENTS

Examiner Initial	Ref.	Author, Title, Source, Date
	EL	Ayyoub M et al, Lack of Tumor Recognition by hTERT Peptide 540-548-Specific CD8 ⁺ T Cells from Melanoma Patients Reveals Inefficient Antigen Processing, Eur J Immunol 31:2642 (2001)
	EM	Bellone M et al, <i>In Vitro</i> Priming of Cytotoxic T Lymphocytes Against Poorly Immunogenic Epitopes by Engineered Antigen-Presenting Cells, Eur J Immunol 24:2691 (1994)
	EN	Bellone M et al, Rejection of a Nonimmunogenic Melanoma by Vaccination with Natural Melanoma Peptides on Engineered Antigen-Presenting Cells, J Immunol 158:783 (1997)
	EO	Boczkowski D et al, Dendritic Cells Pulsed with RNA are Potent Antigen-Presenting Cells in Vitro and in Vivo, J Exp Med 184:465 (1996)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**

Form 1449 (modified)	Docket: 018/213C	U.S.S.N.: 10/044,692
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Title: Human Telomerase Catalytic Subunit: Diagnostic and Therapeutic Methods Inventors: Thomas R. Cech, <i>et al.</i>	
(Use Several Sheets if Necessary)	Filing Date: January 11, 2002	Group: 1642



OTHER DOCUMENTS

Examiner Initial	Author, Title, Source, Date
EP	Proakis M et al, Dendritic Cells Reconstituted with Human Telomerase Gene Induce Potent Cytotoxic T-Cell Response Against Different Types of Tumors, Cancer Gene Therapy 10:239 (2003)
EQ	Greener M, Telomerase: The Search for a Universal Cancer Vaccine, Mol Med Today 6:257 (2000)
ER	Heiser A et al, Human Dendritic Cells Transfected with Renal Tumor RNA Stimulate Polyclonal T-Cell Responses Against Antigens Expressed by Primary and Metastatic Tumors, Cancer Res 61:3388 (2001)
ES	Heiser A et al, Induction of Polyclonal Prostate Cancer-Specific CTL Using Dendritic Cells Transfected with Amplified Tumor RNA, J Immunol 166:2953 (2001)
ET	Hernández J et al, Identification of a Human Telomerase Reverse Transcriptase Peptide of Low Affinity for HLA A2.1 that Induces Cytotoxic T Lymphocytes and Mediates Lysis of Tumor Cells, PNAS 99(19):12275 (2002)
EU	Minev B et al, Cytotoxic T Cell Immunity Against Telomerase Reverse Transcriptase in Humans, PNAS 97(9):4796 (2000)
EV	Nair SK et al, Antigen-Presenting Cells Pulsed with Unfractionated Tumor-Derived Peptides are Potent Tumor Vaccines, Eur J Immunol 27:589 (1997)
EW	Nair SK et al, Induction of Cytotoxic T Cell Responses and Tumor Immunity Against Unrelated Tumors Using Telomerase Reverse Transcriptase RNA Transfected Dendritic Cells, Nat Med 6(8):1011 (2000)
EX	Ping L et al, Dramatic Increase of Telomerase Activity During Dendritic Cell Differentiation and Maturation, J Leukoc Biol 74:270 (2003)
EY	Su Z et al, Immunological and Clinical Responses in Metastatic Renal Cancer Patients Vaccinated with Tumor RNA-Transfected Dendritic Cells, Cancer Res 63:2127 (2003)

Examiner	Date Considered

Examiner: Initial if citation considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. **Include copy of this form with next communication to applicant.**